808 related articles for article (PubMed ID: 25425467)
21. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
22. CARTs for Solid Tumors: Feasible or Infeasible?
Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
[TBL] [Abstract][Full Text] [Related]
23. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
Liu L; Sun M; Wang Z
Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
25. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
26. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
27. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
29. Development of CAR T cells designed to improve antitumor efficacy and safety.
Jaspers JE; Brentjens RJ
Pharmacol Ther; 2017 Oct; 178():83-91. PubMed ID: 28342824
[TBL] [Abstract][Full Text] [Related]
30. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
31. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
32. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
Han EQ; Li XL; Wang CR; Li TF; Han SY
J Hematol Oncol; 2013 Jul; 6():47. PubMed ID: 23829929
[TBL] [Abstract][Full Text] [Related]
34. [CAR T-cell therapy: Balance of efficacy and safety].
Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
[TBL] [Abstract][Full Text] [Related]
35. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Chmielewski M; Hombach AA; Abken H
Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
[TBL] [Abstract][Full Text] [Related]
36. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
[TBL] [Abstract][Full Text] [Related]
37. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
38. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
39. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer.
Chmielewski M; Abken H
Cancer Immunol Immunother; 2012 Aug; 61(8):1269-77. PubMed ID: 22274776
[TBL] [Abstract][Full Text] [Related]
40. [Research Progress on Chimeric Antigen Receptor T Cells-Review].
Zhuang RM; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1829-1832. PubMed ID: 29262925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]